China-headquartered XtalPi has entered a USD 5.9 billion collaboration with US biotech DoveTree to discover small molecule and antibody candidates for oncology, immunology, neurology and metabolic disorders using its AI-robotics platform. The deal includes USD 51 million upfront, USD 49 million in near-term payments and up to USD 5.89 billion in milestones plus royalties. XtalPi's quantum physics-driven platform integrates AI, cloud computing and robotics to accelerate drug discovery across multiple industries including agriculture and energy.

Founded in 2015 by physicists, XtalPi has expanded its AI drug discovery capabilities beyond biopharma. The company will design novel compounds for DoveTree's selected targets while retaining rights to apply its platform for other partners. This marks one of China's largest AI-powered drug discovery deals in 2025.

According to PharmCube's NextBiopharm® database, this partnership has the largest reported value among the 41 deals XtalPi has entered so far. Click here to request a free trial for NextBiopharm®.